26eP Trastuzumab deruxtecan in HER2-positive or ERBB2-mutated tumours: Real-world clinical practice data
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody-drug conjugate approved for HER2-positive breast and gastric cancer, and for ERBB2-mutated non-small-cell lung. Phase II trials (Destiny-PanTumour01 and -02) have reported antitumour activity in other HER2-overexpressing or ERBB2-mutated malignancies. However, evidence in actual clinical practice is limited.
Fields of Study & Subjects
HER2/EGFR in Cancer Research
Lung Cancer Treatments and Mutations
Gastric Cancer Management and Outcomes
Publication details
- Journal / source
- ESMO Open
- Volume
- 11
- Pages
- 106129–106129
- Publication date
- 1 April 2026
- Language
- EN